---
layout: post
title: "Determination That ENDEP (Amitriptyline Hydrochloride) Oral Concentrate, 40 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 19:00:46 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-20195
original_published: 2022-09-19 00:00:00 +0000
significance: 8.00
---

# Determination That ENDEP (Amitriptyline Hydrochloride) Oral Concentrate, 40 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 19, 2022 00:00 UTC
**Document Number:** 2022-20195

## Summary

The Food and Drug Administration (FDA or Agency) has determined that ENDEP (amitriptyline hydrochloride) oral concentrate, 40 milligrams (mg)/milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for ENDEP (amitriptyline hydrochloride) oral concentrate, 40 mg/mL, if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/19/2022-20195/determination-that-endep-amitriptyline-hydrochloride-oral-concentrate-40-milligramsmilliliter-was)
- API: https://www.federalregister.gov/api/v1/documents/2022-20195

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
